ACP
GPCR icon

Acuta Capital Partners’s Structure Therapeutics GPCR Stock Holding History

Acuta Capital Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$252K – 47
2023
Q3 		$252K Buy
+5,000
New +$161K 0.17% 41

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Acuta Capital Partners's GPCR Position: Q4 2023 in Review

Acuta Capital Partners sold out of Structure Therapeutics (GPCR) in Q4 2023, closing a stake of 5,000 shares — an estimated $252K sold.

Acuta Capital Partners first reported a position in GPCR in Q3 2023 and held it in 1 quarter. The position peaked at $252K in Q3 2023. 121 funds tracked by Wall St. Rank hold GPCR as of Q4 2023.

  • Acuta Capital Partners reported no remaining Structure Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 5,000 Structure Therapeutics shares in Q4 2023, an estimated $252K.
  • Acuta Capital Partners first reported a position in Structure Therapeutics in Q3 2023 and held it in 1 quarter.
  • Acuta Capital Partners's Structure Therapeutics position peaked at $252K in Q3 2023.
  • 121 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.